phosphorylcholine has been researched along with rosiglitazone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Acquaviva, F; Castaldo, I; Cocozza, S; Filla, A; Marmolino, D; Monticelli, A; Pinelli, M | 1 |
| Bhatt, AP; Bhende, PM; Damania, B; Dittmer, DP; Roy, D; Sin, SH | 1 |
2 other study(ies) available for phosphorylcholine and rosiglitazone
| Article | Year |
|---|---|
PPAR-gamma agonist Azelaoyl PAF increases frataxin protein and mRNA expression: new implications for the Friedreich's ataxia therapy.
Topics: Cell Line, Tumor; Cells, Cultured; Cerebellum; Fibroblasts; Frataxin; Friedreich Ataxia; Humans; Hypoglycemic Agents; Iron-Binding Proteins; Phosphorylcholine; PPAR gamma; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Transcriptional Activation; Up-Regulation | 2009 |
Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autocrine Communication; Cell Line, Tumor; Cell Proliferation; Cytokines; Humans; Imidazoles; Intracellular Signaling Peptides and Proteins; Lymphoma, Primary Effusion; Mice; Mice, Inbred NOD; Mice, SCID; Paracrine Communication; Phosphoinositide-3 Kinase Inhibitors; Phosphorylcholine; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Quinolines; Rosiglitazone; Thiazolidinediones; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2010 |